McKesson Sells 13% Stake in Medical-Surgical Unit to Apollo for $1.25B

What happened

McKesson Corporation agreed to sell a minority ownership interest in its Medical-Surgical Solutions (MMS) division to funds managed by Apollo affiliates. Apollo Funds will invest $1.25 billion in convertible preferred equity for approximately 13% of the unit, implying a total valuation of roughly $13 billion for MMS. McKesson will retain operating control and majority ownership of MMS and will continue to consolidate its financial results. The transaction is subject to regulatory approvals and customary closing conditions. McKesson first announced its intention to separate MMS through an initial public offering in May 2025, and the IPO remains on track for the second half of calendar year 2027, subject to market conditions and regulatory approvals. On January 1, the company reached a milestone with transition service agreements in place across the enterprise.

Why it matters

This transaction represents a strategic step in McKesson's broader plan to streamline its business portfolio and focus on higher-growth, higher-margin opportunities such as specialty cancer drugs and medications. MMS has experienced sluggish growth since 2020 due to shifting demand, lower volumes in physician office settings, supply chain disruptions, and the post-pandemic environment. In the fiscal third quarter ended December 31, MMS generated $3 billion in revenue (up 1%) but saw segment operating profit fall 10% to $265 million, attributed to lower volumes and reduced seasonal illness incidence. The unit represented only 3.2% of total corporate revenue at the time of the initial separation announcement. By carving out MMS, McKesson aims to unlock value for shareholders while establishing a well-capitalized, standalone medical-surgical supply company. Apollo brings experience in complex carve-outs and public market transactions, which could support MMS's transition to an independent public entity.

Bigger picture

McKesson has a track record of portfolio simplification through divestitures, including its 2020 exit from Change Healthcare. According to company executives, these actions have streamlined the company, sharpened strategy, and created significant shareholder value, including more than doubling returns on invested capital. The separation of MMS aligns with McKesson's long-term enterprise strategy to concentrate on high-growth segments within the healthcare services sector. Apollo, a global alternative asset manager with approximately $938 billion in assets under management as of December 31, 2025, views MMS as a strong market player with a key role in healthcare supply chains outside hospital settings. The deal underscores investor interest in healthcare infrastructure and supply chain businesses, even those experiencing moderate near-term growth challenges.

What to watch

Key upcoming signals include regulatory approval progress for the Apollo transaction and any updates on the timeline for the MMS initial public offering, currently targeted for the second half of 2027. Investors should monitor MMS's quarterly revenue and operating profit trends, particularly volume trends in physician office settings and demand for specialty pharmaceuticals distributed through the unit. Additionally, watch for announcements regarding the structure and final valuation of the IPO, as well as how McKesson deploys capital following the separation. Market conditions and investor appetite for healthcare supply chain businesses will also influence the timing and success of the public listing.

This article was generated by Quantli AI using publicly available news sources.